MetaCap

Harrow (HROW) vs Mineralys Therapeutics (MLYS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Harrow (HROW) has outperformed Mineralys Therapeutics (MLYS) over the past year, losing 21.8% versus a loss of 67.4%. Mineralys Therapeutics is the larger company by market cap ($1.21 billion vs $1.14 billion), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

HROW-21.85%MLYS-67.38%
+46%-13%-73%
Nov 21, 20251 yearNov 20, 2026
HROW+63.32%MLYS-25.92%
+222%+71%-80%
Feb 6, 20235 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

HROW versus MLYS key metrics
MetricHROWMLYS
Share price$30.41$13.66
Market cap$1.14B$1.21B
1-day change-5.35%-3.53%
YTD return-37.94%-62.36%
1-year return-21.85%-67.38%
5-year return+196.11%—
Forward P/E16.26—
EPS (TTM)$-0.76$-4.30
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$272.30M—
Revenue growth (YoY)+36.41%—
Net income (latest FY)$-5.14M$-154.65M
Gross margin75.05%—
Operating margin11.21%—
Net margin-1.89%—
52-week high$54.85$44.13
52-week low$25.76$13.57
Distance from 52-week high-44.56%-69.05%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+104.70%+218.89%
Average volume626.20K1.55M
Shares outstanding37.53M88.56M
Employees37376
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • HROW has outperformed MLYS by 45.5 percentage points over the past year.

About Harrow

HROW stock →

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments.

Health Care · Biotechnology: Pharmaceutical Preparations · 373 employees

About Mineralys Therapeutics

MLYS stock →

Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

HROW vs MLYS FAQ

Which is bigger, Harrow or Mineralys Therapeutics?

Mineralys Therapeutics (MLYS) is larger, with a market capitalization of $1.21B compared with $1.14B for Harrow (HROW).

Which stock has performed better over the past year, HROW or MLYS?

HROW returned -21.85% over the past 12 months, compared with -67.38% for MLYS (price return, excluding dividends). Past performance does not predict future results.

Are Harrow and Mineralys Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons